grant
From therapeutic mechanisms to unraveling the pathophysiology of MS
Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY2025AcuteAddressAgeAge DistributionAge YearsAntihistaminesAutomobile DrivingAxonBiological FunctionBiological MarkersBiological ProcessBlood - brain barrier anatomyBlood-Brain BarrierBody TissuesBrainBrain Nervous SystemCNS Nervous SystemCardiovascularCardiovascular Body SystemCardiovascular Organ SystemCardiovascular systemCausalityCell BodyCell Communication and SignalingCell DeathCell SignalingCellsCentral Nervous SystemCerebrospinal FluidCessation of lifeClinicalClinical ResearchClinical StudyClinical TrialsCombined Modality TherapyComplexContrast-Enhancing LesionDataDeathDemyelinationsDiseaseDisorderDisseminated SclerosisDrugsDysfunctionEncephalonEnhancing LesionEtiologyFDA approvedFumaratesFunctional disorderFutureGadolinium-Enhancing LesionGd-Enhancing LesionHeart VascularHemato-Encephalic BarrierHortega cellHumanImmuneImmunesInflammationInflammatoryInjuryInterventionIntracellular Communication and SignalingLaboratoriesLesionLifelong disabilityLinkMR ImagingMR TomographyMRIMRIsMS LesionsMS patientMS treatmentMagnetic Resonance ImagingMapsMeasurableMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMedicineMedulla SpinalisMental DepressionMeta-AnalysisMetabolicMethodologyMicrogliaModelingModern ManMolecularMultimodal TherapyMultimodal TreatmentMultiple SclerosisMultiple Sclerosis LesionsMuscarinic Acetylcholine ReceptorMuscarinic ReceptorsMyelinNMR ImagingNMR TomographyNervous System DiseasesNervous System DisorderNeuraxisNeurologic DeficitNeurologic DisordersNeurological DisordersNeurological disabilityNuclear Magnetic Resonance ImagingOligodendrocytesOligodendrocytusOligodendrogliaOligodendroglia CellOnset of illnessOutcomeParticipantPathogenicityPathologyPathway interactionsPatientsPermanent disabilityPersonsPharmaceutical PreparationsPharmacodynamicsPhysiopathologyPioglitazonePopulationProcessProteomicsProtocolProtocols documentationRandomization trialRelapseRelapsing-Remitting Multiple SclerosisResearchResidualResidual stateSafetySeveritiesSignal TransductionSignal Transduction SystemsSignalingSingle-Nucleus SequencingSpinal CordTestingTherapeuticTherapeutic AgentsTissuesToxic effectToxicitiesZeugmatographyagesarmbio-markersbiologic markerbiological signal transductionbiomarkerbloodbrain barrierbrain tissuecausationcerebral spinal fluidcirculatory systemcombination therapycombined modality treatmentcombined treatmentcompare to controlcomparison controldecrease disabilitydecrease in disabilitydemyelinatedepressiondisabilitydisability reductiondisease causationdisease onsetdisorder onsetdrivingdrug candidatedrug/agentefficacy testinggitter cellinhibitorinjuriesinsular sclerosisknowledge baselab assignmentlab experimentlaboratory activitylaboratory assignmentlaboratory exerciselaboratory experimentlessen disabilitymesogliamicroglial cellmicrogliocyteminimize disabilitymitigate disabilitymulti-modal therapymulti-modal treatmentmultiple sclerosis patientmultiple sclerosis therapymultiple sclerosis treatmentnecrocytosisneurological diseasenoveloff-label applicationoff-label prescribingoff-label usepathophysiologypathwaypatients with MSpatients with multiple sclerosispeople with Multiple sclerosisperivascular glial cellphase 2 trialphase II trialprecision medicineprecision-based medicineprospectiverandomized trialre-myelinatere-myelinationreduction in disabilityremyelinateremyelinationrepairrepairedsNuc-Seqscreeningscreeningssingle nucleus RNA-sequencingsingle nucleus seqsingle-nucleus RNA-seqslow disabilitysnRNA sequencingsnRNA-seqspinal fluidsystemic inflammationsystemic inflammatory response
Description preview
At disease onset, relapsing–remitting MS (RRMS) is marked by focal inflammatory lesions visible as MRI contrast-enhancing lesions (CELs). CELs reflect blood–brain barrier opening with an influx of immune cells. This focal inflammation damages the central nervous system (CNS), causing demyelination and axonal transection, and can produce acute…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click